COVID-19 Update: Information and resources can be found here.

News

Dr. Prasanna Alluri receives a $1.5 million grant from Department of Defense

Dr. Prasanna Alluri receives a $1.5 million grant from Department of Defense

Dr. Prasanna Alluri, a physician scientist in our breast DOT, received a $1.5 million Breast Cancer Research Program Breakthrough Award from the Department of Defense (DOD) in partnership with Dr. Ram Mani in the Department of Pathology at UT Southwestern. Their study will define how reprogramming of transcriptional and DNA repair pathways drives resistance to endocrine therapies and CDK4/6 inhibitors in breast cancer patients. They will also develop new targeted therapies that reverse treatment resistance by targeting this pathological reprogramming, thereby expanding treatment options for breast cancer patients who have become unresponsive to existing treatments. Breast cancer grants funded by DOD are some of most competitive federal grants with a funding rate of only 5-6%.

AAPM/COMP Meeting 2020

AAPM/COMP Meeting 2020

This year's joint AAPM/COMP meeting was held virtually July 12 - 16. This year's theme was Improving Health Quality. Increasing Global Impact. Our Department participated in dozens of posters and presentations.

Dr. Aguilera receives Damon Runyon Award to study emerging immunotherapy

Dr. Aguilera receives Damon Runyon Award to study emerging immunotherapy

The Damon Runyon Cancer Research Foundation recently named Dr. Aguilera as one of four new Damon Runyon Clinical Investigators. The three-year, $600,000 award supports outstanding early career physician-scientists conducting patient-oriented cancer research with the potential to impact cancer diagnosis, prevention, and treatment.

Dr. Aguilera wins funding award

Dr. Aguilera wins funding award

Dr. Todd Aguilera, Assistant Professor of Radiation Oncology at UTSW, has received a Damon Runyon Clinical Investigator Award for his work in immunotherapy. The award grants Aguilera’s multidisciplinary team $600,000 to support their research.

Brock Sishc hired by NASA's Johnson Space Center

Brock Sishc hired by NASA's Johnson Space Center

Brock Sishc, Ph.D., part of UTSW since 2014, has been recruited by NASA's Johnson Space Center to serve as the cancer discipline lead within the Space Radiation Element, a part of the Human Research Program. Brock's primary role will be to support the chief and deputy element scientists in the direction and development of research goals including gaining an understanding of the risk of space radiation exposure to astronaut health. Congratulations Brock!

Debabrata Saha, Ph.D., receives a $250,000 AACR-Novocure research grant award

Debabrata Saha, Ph.D., receives a $250,000 AACR-Novocure research grant award

Debabrata Saha, Ph.D., part of our Molecular Radiation Biology team, received a $250,000 AACR-Novocure research grant award from the American Association for Cancer Research (AACR) for tumor-treating field research. His research project is titled “Evaluating efficacy of TTFields and radiotherapy in preclinical tumor model.”

Dr. Karanam receives AACR-Novocure Career Development award

Dr. Karanam receives AACR-Novocure Career Development award

Narasimha Kumar Karanam, Ph.D., recently received AACR-Novocure Career Development award from the American Association for Cancer Research (AACR), which awards him a three-year grant of $225,000 to study system-level effects through trans-omics approach and to find novel combination therapies together with Tumor-Treating Fields.

UT Southwestern nearly doubles lifespan of mice with brain cancer

UT Southwestern nearly doubles lifespan of mice with brain cancer

UT Southwestern Simmons Cancer Center researchers have developed technology that is spawning a much better form of drug delivery for gene therapy and has achieved a 43 percent increase in the survival of mice with glioblastoma, one of the deadliest forms of human brain cancer. The researchers used specially engineered silicon chips to zap cells and produce a new drug delivery system. The results were published in Nature Biomedical Engineering.

Why a Promising, Potent Cancer Therapy Isn't Used in the US

Why a Promising, Potent Cancer Therapy Isn't Used in the US

Carbon ion therapy is similarly precise, but because carbon ions are heavier, they deliver more cancer-killing power than protons do. Carbon centers have reported impressive survival rates, particularly for hard-to-treat bone and soft-tissue cancers such as spinal tumors.

Leveraging Compound Promiscuity to Identify Targetable Cysteines within the Kinome

Leveraging Compound Promiscuity to Identify Targetable Cysteines within the Kinome

Covalent kinase inhibitors, which typically target cysteine residues, represent an important class of clinically relevant compounds. Approximately 215 kinases are known to have potentially targetable cysteines distributed across 18 spatially distinct locations proximal to the ATP-binding pocket. However, only 40 kinases have been covalently targeted, with certain cysteine sites being the primary focus. Members of the Westover lab worked with collaborators to develop a strategy that combines the use of a multi-targeted acrylamide-modified inhibitor, SM1-71, with a suite of complementary chemoproteomic and cellular approaches to identify an additional 23 targetable cysteines.

Inaugural AACR-novocure tumor-treating fields research grant recipients announced at AACR annual meeting 2019

Inaugural AACR-novocure tumor-treating fields research grant recipients announced at AACR annual meeting 2019

The recipients of the AACR-Novocure Tumor Treating Fields research grants were announced on April 2 at the American Association for Cancer Research (AACR) Annual Meeting 2019 in Atlanta.

Competing for RAS - Understanding KRAS and the Effects of Its Interactions for Potential Lung Adenocarcinoma Treatment

Competing for RAS - Understanding KRAS and the Effects of Its Interactions for Potential Lung Adenocarcinoma Treatment

With support from a fiscal year 2015 (FY15) Lung Cancer Research Program (LCRP) New Investigator Idea Development award, Dr. Kenneth Westover studied the interactions between KRAS and potential therapeutic small molecule inhibitors.

Researchers demonstrate RAS dimers are essential for cancer

Researchers demonstrate RAS dimers are essential for cancer

Researchers at UT Southwestern’s Simmons Cancer Center have shown that RAS molecules act in pairs, known as dimers, to cause cancer, findings that could help guide them to a treatment.

44 Faces Representing the Future of Biochemistry

44 Faces Representing the Future of Biochemistry

Dr. Kenneth Westover was named one of "44 Faces Representing the Future of Biochemistry" in the January 9 special issue of Biochemistry.Dr. Westover, part of our Radiation Oncology lung team, has a lab that focuses on developing new, targeted cancer therapies.

UTSW receives national recognition

UTSW receives national recognition

U.S. News & World Report just released its 2017 list of top hospitals. UT Southwestern ranks #1 in the Dallas/Ft. Worth area and #2 in Texas. In addition, we nationally ranked in six specialties and are noted as high-performing in four conditions, including cancer. An honor to be recognized!

A new chapter in radiation oncology

A new chapter in radiation oncology

UT Southwestern’s Harold C. Simmons Comprehensive Cancer Center is one of the nation’s top destinations for patients seeking cancer treatments. Now it has a new radiation oncology building to call home that’s as sterling as its reputation.

High-tech radiation oncology building opens its doors

High-tech radiation oncology building opens its doors

UT Southwestern’s Harold C. Simmons Comprehensive Cancer Center is one of the nation’s top destinations for patients seeking cancer treatments. Now it has a new radiation oncology building to call home that’s as sterling as its reputation.

Researchers uncover mechanism for cancer-killing properties of pepper plant

Researchers uncover mechanism for cancer-killing properties of pepper plant

UT Southwestern Medical Center scientists have uncovered the chemical process behind anti-cancer properties of a spicy Indian pepper plant called the long pepper, whose suspected medicinal properties date back thousands of years.

Cancer investigators receive major donor-funded grants for combined immunotherapy and radiation research

Cancer investigators receive major donor-funded grants for combined immunotherapy and radiation research

Neil Desai, M.D., Ph.D., Assistant Professor of Radiation Oncology, has been appointed a Dedman Family Scholar in Clinical Care, an honor that comes with a $600,000, four-year grant. Two other physician-led grants were awarded by the Lupe Murchison Foundation and the Once Upon a Time Foundation.

Role for SABR in metastatic renal cell cancer

Role for SABR in metastatic renal cell cancer

Dr. Raquibul Hannan is interviewed on Cancer Network about stereotactic ablative radiotherapy (SABR) for advanced kidney cancer.

Speaker roundup for September

Speaker roundup for September

Department of Radiation Oncology faculty gave invited lectures at the following events recently:

New faculty members and promotions in Radiation Oncology

New faculty members and promotions in Radiation Oncology

Andrei Pugachev, Ph.D., is a new Assistant Professor in our Physics Division, while Heeyoun Bunch, Ph.D., joins the Molecular Radiation Biology Division as an Instructor.

New laboratory opens under Davis

New laboratory opens under Davis

Assistant Professor Tony Davis, Ph.D., has been made an independent in­vestigator in the department’s Division of Molecular Radiation Biology.

Neutrophils are key to harnessing anti-tumor immune response from radiation therapy, study finds

Neutrophils are key to harnessing anti-tumor immune response from radiation therapy, study finds

Combining targeted radiation therapy with a neutrophil stimulant enhances anti-tumor immunity, according to new research into cancer immunology at UT Southwestern Medical Center

Grants awarded to Radiation Oncology researchers

Grants awarded to Radiation Oncology researchers

Grants totaling more than $2.6 million have been awarded to researchers in medical physics and molecular radiation biology.

Speaker roundup for June

Speaker roundup for June

Department of Radiation Oncology faculty gave invited lectures at the following events recently:

Texans want in on cancer "moonshot"

Texans want in on cancer "moonshot"

Our heavy ion initiative was highlighted during a national summit on cancer led by Vice President Joe Biden.

Department makes heavy ion grant awards

Department makes heavy ion grant awards

The Department of Radiation Oncology at UT Southwestern Medical Center has awarded five, two-year seed grants of $100,000 apiece to Texas researchers to facilitate research related to heavy ion therapy.

NASA awards funds to study effects of space radiation during Mars mission

NASA awards funds to study effects of space radiation during Mars mission

UT Southwestern Medical Center researchers have been awarded $3.6 million in NASA funds to study how space radiation would affect the cancer risk of astronauts taking part in deep space missions to Mars.

With CPRIT grants, new approaches for pediatric cancer treatment

With CPRIT grants, new approaches for pediatric cancer treatment

Investigators in the Department of Radiation Oncology were awarded close to $2.7 million in the latest round of funding from the Cancer Prevention and Research Institute of Texas (CPRIT) to study and treat childhood cancer.

Researchers develop classification model for cancers caused by most frequently mutated cancer gene

Researchers develop classification model for cancers caused by most frequently mutated cancer gene

UT Southwestern Medical Center researchers have developed a classification for cancers caused by KRAS, the most frequently mutated gene in cancer, that could eventually help oncologists choose more effective, customized cancer therapies.

UTSW receives key NCI funding to plan first U.S. Center for Heavy Ion Radiation Therapy Research

UTSW receives key NCI funding to plan first U.S. Center for Heavy Ion Radiation Therapy Research

The National Cancer Institute (NCI) of the National Institutes of Health awarded UT Southwestern a $1 million planning grant to establish the country’s first National Center for Heavy Ion Radiation Therapy.

Cancer researchers identify irreversible inhibitor for KRAS gene mutation

Cancer researchers identify irreversible inhibitor for KRAS gene mutation

UT Southwestern Medical Center cancer researchers have found a molecule that selectively and irreversibly interferes with the activity of a mutated cancer gene common in 30 percent of tumors.

Blocking DNA repair could improve radiation therapy for brain cancer

Blocking DNA repair could improve radiation therapy for brain cancer

UT Southwestern Medical Center researchers have demonstrated in both cancer cell lines and in mice that blocking critical DNA repair mechanisms could improve the effectiveness of radiation therapy for highly fatal brain tumors called glioblastomas.